Home » Newsletters » BioWorld Science

BioWorld Science

March 9, 2022

View Archived Issues

Abbisko Therapeutics identifies new EGFR inhibitors

New ibuprofen derivatives divulged by Nanjing Heron Pharmaceutical Science and Technology

Nanjing Shunxin Pharmaceutical, Jiangsu Chia Tai Tianqing Pharmaceutical Group patent ADCs

P2RX3 antagonists discovered at Tuojie Biotech

TNIK Therapeutics presents new prodrugs of TNIK inhibitors

Zinc oxide nanoparticles target integrin alpha-v beta-3 for breast cancer treatment

New lipid nanoparticles allow mRNA delivery to the lung for treating lymphangioleiomyomatosis

BAL-0891 shows potent single agent activity in mouse model of TNBC

ATH-1020, a novel HGF/MET positive modulator with promising preclinical efficacy

Ghost mitochondria drive tumor progression through EIF2AK4/Akt signaling

ESMO TAT: Heating cold tumors one subtype, and one cell type, at a time

Funding for Psilera's evaluation of novel DMT derivatives for mood and addiction disorders

NIH grant supports cholera research at Illinois Institute of Technology

Targeting iASPP-TMCO1 axis may represent a promising therapeutic target in cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.